252 related articles for article (PubMed ID: 26790476)
1. Lack of MG53 in human heart precludes utility as a biomarker of myocardial injury or endogenous cardioprotective factor.
Lemckert FA; Bournazos A; Eckert DM; Kenzler M; Hawkes JM; Butler TL; Ceely B; North KN; Winlaw DS; Egan JR; Cooper ST
Cardiovasc Res; 2016 May; 110(2):178-87. PubMed ID: 26790476
[TBL] [Abstract][Full Text] [Related]
2. MG53 participates in ischaemic postconditioning through the RISK signalling pathway.
Zhang Y; Lv F; Jin L; Peng W; Song R; Ma J; Cao CM; Xiao RP
Cardiovasc Res; 2011 Jul; 91(1):108-15. PubMed ID: 21285295
[TBL] [Abstract][Full Text] [Related]
3. Dysferlin, annexin A1, and mitsugumin 53 are upregulated in muscular dystrophy and localize to longitudinal tubules of the T-system with stretch.
Waddell LB; Lemckert FA; Zheng XF; Tran J; Evesson FJ; Hawkes JM; Lek A; Street NE; Lin P; Clarke NF; Landstrom AP; Ackerman MJ; Weisleder N; Ma J; North KN; Cooper ST
J Neuropathol Exp Neurol; 2011 Apr; 70(4):302-13. PubMed ID: 21412170
[TBL] [Abstract][Full Text] [Related]
4. Glucose-Sensitive Myokine/Cardiokine MG53 Regulates Systemic Insulin Response and Metabolic Homeostasis.
Wu HK; Zhang Y; Cao CM; Hu X; Fang M; Yao Y; Jin L; Chen G; Jiang P; Zhang S; Song R; Peng W; Liu F; Guo J; Tang L; He Y; Shan D; Huang J; Zhou Z; Wang DW; Lv F; Xiao RP
Circulation; 2019 Feb; 139(7):901-914. PubMed ID: 30586741
[TBL] [Abstract][Full Text] [Related]
5. MG53 constitutes a primary determinant of cardiac ischemic preconditioning.
Cao CM; Zhang Y; Weisleder N; Ferrante C; Wang X; Lv F; Zhang Y; Song R; Hwang M; Jin L; Guo J; Peng W; Li G; Nishi M; Takeshima H; Ma J; Xiao RP
Circulation; 2010 Jun; 121(23):2565-74. PubMed ID: 20516375
[TBL] [Abstract][Full Text] [Related]
6. MG53 E3 Ligase-Dead Mutant Protects Diabetic Hearts From Acute Ischemic/Reperfusion Injury and Ameliorates Diet-Induced Cardiometabolic Damage.
Feng H; Shen H; Robeson MJ; Wu YH; Wu HK; Chen GJ; Zhang S; Xie P; Jin L; He Y; Wang Y; Lv F; Hu X; Zhang Y; Xiao RP
Diabetes; 2022 Feb; 71(2):298-314. PubMed ID: 34844991
[TBL] [Abstract][Full Text] [Related]
7. MG53 anchored by dysferlin to cell membrane reduces hepatocyte apoptosis which induced by ischaemia/reperfusion injury in vivo and in vitro.
Yao W; Li H; Han X; Chen C; Zhang Y; Tai WL; Xia Z; Hei Z
J Cell Mol Med; 2017 Oct; 21(10):2503-2513. PubMed ID: 28401647
[TBL] [Abstract][Full Text] [Related]
8. Cardiac Ischemic Preconditioning Promotes MG53 Secretion Through H
Shan D; Guo S; Wu HK; Lv F; Jin L; Zhang M; Xie P; Wang Y; Song Y; Wu F; Lan F; Hu X; Cao CM; Zhang Y; Xiao RP
Circulation; 2020 Sep; 142(11):1077-1091. PubMed ID: 32677469
[TBL] [Abstract][Full Text] [Related]
9. Membrane repair defects in muscular dystrophy are linked to altered interaction between MG53, caveolin-3, and dysferlin.
Cai C; Weisleder N; Ko JK; Komazaki S; Sunada Y; Nishi M; Takeshima H; Ma J
J Biol Chem; 2009 Jun; 284(23):15894-902. PubMed ID: 19380584
[TBL] [Abstract][Full Text] [Related]
10. Cardioprotection of recombinant human MG53 protein in a porcine model of ischemia and reperfusion injury.
Liu J; Zhu H; Zheng Y; Xu Z; Li L; Tan T; Park KH; Hou J; Zhang C; Li D; Li R; Liu Z; Weisleder N; Zhu D; Lin P; Ma J
J Mol Cell Cardiol; 2015 Mar; 80():10-19. PubMed ID: 25533937
[TBL] [Abstract][Full Text] [Related]
11. MG53: Biological Function and Potential as a Therapeutic Target.
Zhang Y; Wu HK; Lv F; Xiao RP
Mol Pharmacol; 2017 Sep; 92(3):211-218. PubMed ID: 28432201
[TBL] [Abstract][Full Text] [Related]
12. Dysferlin interacts with calsequestrin-1, myomesin-2 and dynein in human skeletal muscle.
Flix B; de la Torre C; Castillo J; Casal C; Illa I; Gallardo E
Int J Biochem Cell Biol; 2013 Aug; 45(8):1927-38. PubMed ID: 23792176
[TBL] [Abstract][Full Text] [Related]
13. Cardioprotection of ischemia/reperfusion injury by cholesterol-dependent MG53-mediated membrane repair.
Wang X; Xie W; Zhang Y; Lin P; Han L; Han P; Wang Y; Chen Z; Ji G; Zheng M; Weisleder N; Xiao RP; Takeshima H; Ma J; Cheng H
Circ Res; 2010 Jul; 107(1):76-83. PubMed ID: 20466981
[TBL] [Abstract][Full Text] [Related]
14. MG53: A new protagonist in the precise treatment of cardiomyopathies.
Zhao Q; Zhang Q; Zhao X; Tian Z; Sun M; He L
Biochem Pharmacol; 2024 Apr; 222():116057. PubMed ID: 38367817
[TBL] [Abstract][Full Text] [Related]
15. Blocking MG53
Lv F; Wang Y; Shan D; Guo S; Chen G; Jin L; Zheng W; Feng H; Zeng X; Zhang S; Zhang Y; Hu X; Xiao RP
Circ Res; 2022 Dec; 131(12):962-976. PubMed ID: 36337049
[TBL] [Abstract][Full Text] [Related]
16. Calpains, cleaved mini-dysferlinC72, and L-type channels underpin calcium-dependent muscle membrane repair.
Lek A; Evesson FJ; Lemckert FA; Redpath GM; Lueders AK; Turnbull L; Whitchurch CB; North KN; Cooper ST
J Neurosci; 2013 Mar; 33(12):5085-94. PubMed ID: 23516275
[TBL] [Abstract][Full Text] [Related]
17. MG53 is a double-edged sword for human diseases.
Zhang Y; Wu HK; Lv FX; Xiao RP
Sheng Li Xue Bao; 2016 Aug; 68(4):505-16. PubMed ID: 27546510
[TBL] [Abstract][Full Text] [Related]
18. p55γ degrades RIP3 via MG53 to suppress ischaemia-induced myocardial necroptosis and mediates cardioprotection of preconditioning.
Li Z; Dai R; Chen M; Huang L; Zhu K; Li M; Zhu W; Li Y; Xie N; Li J; Wang L; Lan F; Cao CM
Cardiovasc Res; 2023 Nov; 119(14):2421-2440. PubMed ID: 37527538
[TBL] [Abstract][Full Text] [Related]
19. MG53 is not a critical regulator of insulin signaling pathway in skeletal muscle.
Philouze C; Turban S; Cremers B; Caliez A; Lamarche G; Bernard C; Provost N; Delerive P
PLoS One; 2021; 16(2):e0245179. PubMed ID: 33566837
[TBL] [Abstract][Full Text] [Related]
20. MG53, A Novel Regulator of KChIP2 and I
Liu W; Wang G; Zhang C; Ding W; Cheng W; Luo Y; Wei C; Liu J
Circulation; 2019 Apr; 139(18):2142-2156. PubMed ID: 30760025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
